Ocular Oncology
Harvard University Medical School (MD), Graduate School: Harvard Kennedy School of Government (MPP)
University of Miami, Bascom Palmer Eye Institute (Chief Resident)
Vitreoretinal Surgery - Bascom Palmer Eye Institute, Ocular Oncology – Bascom Palmer Eye Institute
Ocular Oncology, Uveal Melanoma, Retinoblastoma, Choroidal Hemangioma, Ocular Surface tumors (OSSN, conjunctival melanoma, lymphoma, etc.), Ocular Trauma, Complicated retinal Detachment, Proliferative vitreoretinopathy, Diabetic Retinopathy, Macular Hole, Age Related Macular Degeneration, retinal vascular occlusive disease, epiretinal membranes
2023 Top 2 Most Influential Ophthalmologists in the World, The Ophthalmologist (UK)
2023 An Inaugural Inductee in The Ophthalmologist Hall of Fame
Nathan L. Scott, M.D., M.P.P. is an Assistant Professor of Clinical Ophthalmology and the Chief of the Ocular Oncology Division at the Shiley Eye Institute and Viterbi Family Department of Ophthalmology. He treats general and complex vitreoretinal diseases as well as both surface and intraocular malignancies.
Dr. Scott earned his medical degree at Harvard University Medical School and completed his residency in ophthalmology at the University of Miami Bascom Palmer Eye Institute, where he was also selected as Chief Resident. He completed fellowships in Vitreoretinal Surgery and Ocular Oncology at the Bascom Palmer Eye Institute. He received multiple awards during his training, including the Heed Ophthalmic Society Fellowship, the Mary August Trust Fellowship Award, the 2020 Vit Buckle Society Fellows Foray award, and the American Academy of Ophthalmology Robert Copeland Fellowship award.
Dr. Scott is actively engaged with the American Academy Ophthalmology, where he serves on the executive board of the Minority Ophthalmology Mentoring program and is a member of the Young Ophthalmology Advocacy sub-committee.
Dr. Scott is a physician-scientist with a clinical focus on vitreoretinal diseases and surgery, as well as a special interest in ocular oncology. His clinical research and interests include utilizing imaging and genomic/molecular technologies to better understand, diagnose and treat cancers of the eye.